Trial Profile
A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Haemangiosarcoma; Malignant fibrous histiocytoma; Sarcoma
- Focus Therapeutic Use
- 20 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 20 Nov 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 06 Jun 2023 Efficacy results in three histology specific expansion cohorts: 1) UPS/MFS, 2) cutaneous AS and 3) ES presented at the 59th Annual Meeting of the American Society of Clinical Oncology.